The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
IN8bio, Inc. announced that 100% of acute myeloid leukemia (AML) patients treated with its allogeneic gamma-delta T cell therapy, INB-100, remain in complete remission (CR) with a median follow-up of ...
Although survival rates for acute myeloid leukemia (AML) continue to improve, many long-term survivors face persistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results